Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 5/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | UGCG | Q16739 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5225202 | 0.88 | GHSR (0.70) | GHSRMEN1KMT2AUGCG | |
| SCHEMBL5226022 | 0.88 | GHSR (0.70) | GHSRMEN1KMT2AUGCG | |
| SCHEMBL6638381 | 0.88 | GHSR (0.39) | GHSRUGCG | |
| SCHEMBL6789921 | 0.85 | GHSR (0.55) | GHSRMEN1KMT2AUGCG | |
| SCHEMBL6634069 | 0.85 | GHSR (0.54) | GHSRMEN1KMT2AUGCG | |
| SCHEMBL7592436 | 0.78 | AKT1 (0.42) | DPP4 | |
| SCHEMBL7015726 | 0.78 | AKT1 (0.42) | DPP4 | |
| SCHEMBL5228930 | 0.77 | KDM4E (0.35) | GHSRGRM4 | |
| SCHEMBL5226469 | 0.76 | GHSR (0.56) | GHSRKMT2AUGCG | |
| SCHEMBL5226424 | 0.76 | GHSR (0.56) | GHSRKMT2AUGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686359-B2 | ANIMAL GROWTH REGULATORS; OSTEOPOROSIS; CONGESTIVE HEART FAILURE; MUSCULAR DISORDERS | PFIZER INC. | 2004-02-03 | — | — | US | claimed |
| US-20030130284-A1 | Growth hormone secretagogues | CARPINO PHILIP A (US) | 2003-07-10 | — | — | US | claimed |
| US-6559150-B2 | Neurotransmitter stimulants; antidiabetic agents; congestive heart failure; obesity; frailty; maintaining renal and catabolic homeostasis; bone fracture repair; reducing cachexia and protein loss; muscle strength and burns. | PFIZER INC. | 2003-05-06 | — | — | US | claimed |
| US-20020045622-A1 | Growth hormone secretagogues | CARPINO PHILIP A (US) | 2002-04-18 | — | — | US | claimed |
| EP-0995748-A1 | Growth hormone secretagogues | Pfizer Products Inc. (US) | 2000-04-26 | — | — | EP | claimed |
| EP-0995748-B1 | Growth hormone secretagogues | PFIZER PROD INC (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6686359-B2 | ANIMAL GROWTH REGULATORS; OSTEOPOROSIS; CONGESTIVE HEART FAILURE; MUSCULAR DISORDERS | PFIZER INC. | 2004-02-03 | — | — | US | disclosed |
| US-20030130284-A1 | Growth hormone secretagogues | CARPINO PHILIP A (US) | 2003-07-10 | — | — | US | disclosed |
| US-6559150-B2 | Neurotransmitter stimulants; antidiabetic agents; congestive heart failure; obesity; frailty; maintaining renal and catabolic homeostasis; bone fracture repair; reducing cachexia and protein loss; muscle strength and burns. | PFIZER INC. | 2003-05-06 | — | — | US | disclosed |
| US-20020045622-A1 | Growth hormone secretagogues | CARPINO PHILIP A (US) | 2002-04-18 | — | — | US | disclosed |
| US-6358951-B1 | ADMINISTERING PYRAZOLO(4,3-C)PYRIDINE DERIVATIVE TO TREAT OBESITY, CONGESTIVE HEART FAILURE, OSTEOPOROSIS, AGING, BONE AND MUSCULAR DISORDERS | PFIZER INC. | 2002-03-19 | — | — | US | disclosed |
| EP-0995748-A1 | Growth hormone secretagogues | Pfizer Products Inc. (US) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045622-A1 | Growth hormone secretagogues | GHSR, GHRHR, GIPR | GHSR 1/4885MEN1 1111/4885KMT2A 4810/4885 |
| US-20030130284-A1 | Growth hormone secretagogues | GHSR, GHRHR, GIPR | GHSR 1/4885MEN1 1111/4885KMT2A 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.